ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1498

A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions

Tien Nguyen1, Melvin Churchill 2, Robert Levin 3, Guillermo Valenzuela 4, Joseph Merola 5, Alexis Ogdie 6, Ana-Maria Orbai 7, Jose Scher 8, Arthur Kavanaugh 9, Shital Agawane 10, Farid Kianifard 11, Chauncy Rollins 11 and Olivier Chambenoit 11, 1Department of Dermatology, University of California, Irvine, Irvine, CA, 2Arthritis Center of Nebraska, Lincoln, NE, 3Clinical Research of West Florida, Inc and University of South Florida, Clearwater/Tampa, FL, 4Integral Rheumatology & Immunology Specialists, Plantation, FL, 5Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 6Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 7Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 8Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, 9University of California, San Diego School of Medicine, La Jolla, CA, 10Novartis Healthcare Pvt Ltd, Hyderabad, India, 11Novartis Pharmaceuticals Corporation, East Hanover, NJ

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologics, IL-17A and psoriasis, Psoriatic arthritis, secukinumab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine in the pathogenesis of PsA. SEC is approved for treatment of PsA based on the phase 3 FUTURE studies, where SEC proved superior to placebo (PBO) in improving signs and symptoms of PsA. Although pts from several countries were included, US pts were under-represented. We report findings from CHOICE (NCT02798211), a phase 4 study which evaluated SEC vs PBO in US biologic-naive pts with PsA with psoriatic skin lesions.

Methods: CHOICE was a randomized, double-blind, controlled trial conducted in the United States. Biologic-naive pts with active PsA by CASPAR criteria and psoriatic skin lesions (PASI ≥ 1) were enrolled. Pts were randomized 2:2:1 to receive SEC 300 mg, SEC 150 mg, or PBO, respectively, with a weekly loading dose up to Week 4, and every 4 weeks thereafter for 16 weeks. After Week 16, all pts randomized to PBO, and nonresponders from the SEC 150-mg group received SEC 300 mg up to Week 52. The primary objective was to show superiority of SEC 300 mg vs PBO in ACR20 response at Week 16. Secondary and exploratory objectives included the effect of SEC on dactylitis, enthesitis, psoriasis, remission status, RAPID3 score, and safety. Long-term (up to Week 52) efficacy and safety were also assessed.

Results: In total, 258 pts were randomized to SEC 300 mg (n = 103), SEC 150 mg (n = 103), or PBO (n = 52). Pts in all treatment groups had comparable baseline characteristics. In general, pts in CHOICE were older, had a higher mean weight, and higher baseline joint involvement than pts in the FUTURE studies. The study met its primary objective with a greater percentage of pts treated with SEC 300 mg achieving ACR20 response at Week 16 compared with PBO (51.5% vs 23.1%; odds ratio [OR], 3.51 [95% CI: 1.65, 7.45]; P = .0011, using logistic regression) (Figure 1). ACR20 responses were numerically higher with SEC 150 mg than PBO (36.9%; OR, 1.92 [95% CI: 0.89, 4.15]; P = .0961). SEC also led to higher ACR50/70 response rates, higher rates of minimal disease activity, lower RAPID3 scores, and improvements in other variables compared with PBO (Table 1). Response rates were generally sustained over time with SEC, with the percentage of responders increasing after uptitration of SEC dose. The most commonly reported adverse events (AEs) with SEC at Week 16 were diarrhea and upper respiratory tract infections (Table 2). No inflammatory bowel disease was reported; 3 pts (SEC 300 mg, n = 1; SEC 150 mg, n = 2) had Candida infections at Week 16. Only 1 pt in each SEC group discontinued treatment by Week 16 due to AEs. One death occurred during the study (cardiac arrest, PBO group).

Conclusion: SEC 300 mg was superior to PBO in leading to rapid and significant improvements in symptoms of PsA in US biologic-naive patients. Benefits were observed with both SEC doses; however, responses were generally higher with SEC 300 mg. Overall, findings in CHOICE were consistent with previous studies and suggest that SEC 300 mg is safe and efficacious as a first-line biologic treatment for pts with PsA.


Disclosure: T. Nguyen, AbbVie, 2, 5, 8, Amgen, 2, 5, 8, Allmiral, 8, Bristol-Myers Squibb, 2, 5, Biogen Idec, 2, Celgene, 5, 8, Lilly, 2, 5, 8, Corrona, 5, GSK, 2, Janssen, 5, Merck, 2, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Sanofi Regeneron, 2, 5, 8, Sun Pharma, 8, UCB, 5; M. Churchill, Novartis, 2; R. Levin, AbbVie, 2, 8, Amgen, 2, Bristol-Myers Squibb, 8, Gilead, 5, Lilly, 2, Myriad Genetics, 5, Pfizer, 2, Sanofi, 2, 8, UCB, 2; G. Valenzuela, AbbVie, 5, Bristol-Myers Squibb, 2, Celgene, 5, GSK, 5, Janssen, 5, Lilly, 2, 5, Merck, 2, 5, MLKCDT, 2, Novartis, 2, 5, Pfizer, 2, 5, Sanofi Regeneron, 2, 5, UCB, 5; J. Merola, AbbVie, 2, 5, 8, Aclaris, 2, 5, Almirall, 2, 5, Amgen, 5, Biogen, 2, 5, Biogen Idec, 2, 5, Biogen IDEC, 5, Brigham and Women's Hospital, Harvard, 3, Burrage Capital Management Boston Advisory Board, 6, Celgene, 2, 5, Dermavant, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 5, GlaxoSmithKline, 5, GSK, 2, 5, Incyte, 2, 5, Janssen, 2, 5, Leo Pharma, 2, 5, Lilly, 5, Merck, 5, Merck Research Laboratories, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Regeneron, 5, Samumed, 2, 5, Sanofi, 5, Sanofi Regeneron, 2, 5, Science 37, 5, Sun Pharma, 2, 5, UCB, 2, 5; A. Ogdie, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie, BMS, Eli Lilly, Novartis, Pfizer, Takeda, 5, Amgen, 2, 4, 5, 8, Amgen to Forward National Databank, 2, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 4, 5, 8, Corrona, 5, CORRONA, 5, From Noavrtis to husband, 7, Lilly, 5, Lily, 5, Novartis, 2, 5, 7, Novartis to UPenn, 2, Novartis, Pfizer, 2, Pfizer, 2, 5, Pfizer Inc, 2, 5, Pfizer to UPenn, 2; A. Orbai, AbbVie, 2, Celgene, 2, Eli Lilly, 2, 5, Horizon, 2, Janssen, 2, 5, Lilly, 2, 5, Novartis, 2, 5, Pfizer, 5, UCB, 5; J. Scher, Amgen, 5, Bristol-Myers Squibb, 5, Janssen, 5, Novartis, 2, 5, Pfizer, 2, UCB, 5; A. Kavanaugh, Abbott, 2, Abbott, Amgen, AstraZeneca, BMS, Celgene Corporation, Centocor-Janssen, Pfizer, Roche, UCB, 2, Amgen, 2, Bristol-Myers Squibb, 2, Eli Lilly, 5, Eli Lilly and Company, 5, Gilead Sciences, Inc., 2, Janssen, 2, Janssen Research & Development, LLC, 2, Novartis, 2, 5, Pfizer, 2, Pfizer Inc, 2, Roche, 2, UCB Pharma, 2; S. Agawane, Novartis, 3, Novartis Healthcare Pvt Ltd, 3; F. Kianifard, Novartis, 3, 4; C. Rollins, Novartis, 3, 4; O. Chambenoit, Novartis, 3, 4.

To cite this abstract in AMA style:

Nguyen T, Churchill M, Levin R, Valenzuela G, Merola J, Ogdie A, Orbai A, Scher J, Kavanaugh A, Agawane S, Kianifard F, Rollins C, Chambenoit O. A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-randomized-placebo-controlled-study-evaluating-the-safety-and-efficacy-of-secukinumab-in-us-biologic-naive-patients-with-active-psoriatic-arthritis-and-psoriatic-skin-lesions/. Accessed April 11, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomized-placebo-controlled-study-evaluating-the-safety-and-efficacy-of-secukinumab-in-us-biologic-naive-patients-with-active-psoriatic-arthritis-and-psoriatic-skin-lesions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.